Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping the Pharmalot campus this morning, where the short person has left for gainful summer employment and the official mascot is happily snoozing in his corner. As for us, we are staring at the intimidating to-do list and quaffing cups of stimulation. Perhaps you can relate? In any event, we have once again assembled a few items of interest to get you started on your day. So here you go. Hope you conquer the world and keep us in mind when you run across something intriguing. …
Biogen (BIIB) mounted a vigorous defense of its controversial Alzheimer’s drug, Aduhelm, with the head of research and development releasing an open letter to the Alzheimer’s community that took direct aim at critics of approval, STAT writes. Al Sandrock, the R&D chief and an architect of many of Biogen’s successes, wrote that the purpose of the letter was to correct “misinformation and misunderstanding” about the drug and the approval process.
Pfizer (PFE) and BioNTech (BNTX) announced a plan to widen access to Covid-19 vaccines by striking a production deal with a South African company, but the effort was quickly panned by patient advocates who argued the arrangement does not go far enough, STAT tells us. The drug makers said they contracted with The Biovac Institute, a vaccine maker backed in part by the South African government, to assemble the final stages of their Covid-19 vaccine, a process known in the pharmaceutical industry as “fill-and-finish.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect